



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: A. Aguzzi, et al.

Serial No.: 09/554,567

Filed: September 1, 2000

For: DIAGNOSTICS AND THERAPEUTICS  
FOR TRANSMISSIBLE SPONGIFORM  
ENCEPHALOPATHY AND METHODS  
FOR THE MANUFACTURE OF NON-  
INFECTIVE BLOOD PRODUCTS AND  
TISSUE DERIVED PRODUCTS

Examiner: J. Roark

Group Art Unit: 1644

Case No.: 6458.US.O1


Date: June 25, 2001

CERTIFICATE OF MAILING (37 CFR  
1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents  
Washington, D.C. 20231, on:

Date of Deposit: June 25, 2001

  
Wanda E. Smith Date

TECH CENTER 1600/2900

JUL 09 2001

RECEIVED

**STATEMENT UNDER 37 C.F.R. §1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The undersigned, being the agent of record of the above-identified patent application, submits the following statement regarding the Sequence Listing in computer readable (submitted herewith) and paper form:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, are the same; and that they contain no sequence information that would constitute new matter beyond the original submissions.

Respectfully submitted,

A. Aguzzi, et al.



Mimi C. Goller  
Registration No. 39,046  
Attorney for Applicants

Abbott Laboratories  
D-377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-3500  
Phone: (847) 937-7550  
Fax: (847) 938-2623



JUN 29 2001

**Notice to Comply**

Application No.	Applicant(s)	
09/554,567	AGUZZI ET AL.	
Examiner	Art Unit	
Jessica H. Roark	1644	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**